Rxulti

RSS

brexpiprazole

Authorised
This medicine is authorised for use in the European Union.

Overview

Rxulti is an antipsychotic medicine used to treat schizophrenia in adults. Schizophrenia is a mental illness with symptoms such as delusions, disorganised thinking and speech, suspiciousness and hallucinations (seeing, hearing or feeling things that are not there).

Rxulti contains the active substance brexpiprazole.

This EPAR was last updated on 14/06/2023

Authorisation details

Product details
Name
Rxulti
Agency product number
EMEA/H/C/003841
Active substance
brexpiprazole
International non-proprietary name (INN) or common name
brexpiprazole
Therapeutic area (MeSH)
Schizophrenia
Anatomical therapeutic chemical (ATC) code
N05AX16
Publication details
Marketing-authorisation holder
Otsuka Pharmaceutical Netherlands B.V.
Revision
5
Date of issue of marketing authorisation valid throughout the European Union
26/07/2018
Contact address

Herikerbergweg 292
1101 CT Amsterdam
Netherlands

Product information

26/05/2023 Rxulti - EMEA/H/C/003841 - R/0014

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Psycholeptics

Therapeutic indication

Treatment of schizophrenia.

Assessment history

Related content

How useful was this page?

Add your rating
Average
2 ratings
1 rating
2 ratings